Evolocumab + Statins (Cardiovascular Agents)
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hyperlipidemias
Conditions
Hyperlipidemias
Trial Timeline
Feb 17, 2021 → Dec 1, 2024
NCT ID
NCT04608474About Evolocumab + Statins (Cardiovascular Agents)
Evolocumab + Statins (Cardiovascular Agents) is a approved stage product being developed by Amgen for Hyperlipidemias. The current trial status is unknown. This product is registered under clinical trial identifier NCT04608474. Target conditions include Hyperlipidemias.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04608474 | Approved | UNKNOWN |
Competing Products
5 competing products in Hyperlipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atorvastatin + atorvastatin + atorvastatin | Pfizer | Approved | 84 |
| SAL003 140 mg + Placebo | Shenzhen Salubris Pharmaceuticals | Phase 3 | 76 |
| SAL003 140 mg + Placebo | Shenzhen Salubris Pharmaceuticals | Phase 3 | 76 |
| SLN360 + Placebo | Medpace | Phase 1 | 30 |
| Bempedoic Acid + Ezetimibe + Placebos | Esperion Therapeutics | Phase 3 | 72 |